Disseminated tuberculosis in a patient with antinuclear antibody-negative systemic lupus erythematosus: A rare association

Internal Medicine, PGIMER and Dr Ram Manohar Lohia Hospital, New Delhi, India.
Case Reports 01/2013; 2013. DOI: 10.1136/bcr-2012-008101
Source: PubMed


Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with diverse manifestations. Tuberculosis is known to induce and exacerbate SLE and it becomes quite difficult to diagnose tuberculosis in this setting, owing to a similar, overlapping presentation of tuberculosis and SLE. We report a case of disseminated tuberculosis in a patient with antinuclear antibody-negative SLE. Treatment was started with antitubercular drugs together with hydroxychloroquine and steroid. After 6 months of follow-up the patient recovered with treatment.

3 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: To study the incidence and pattern of tuberculosis in patients taking systemic corticosteroids (CS). Seventy seven patients taking oral CS for various respiratory diseases and eighty patients suffering from similar diseases but not receiving steroids were followed up for one year to study the incidence of tuberculosis. Five patients (6.5%) receiving CS developed tuberculosis as against none amongst the controls (p < 0.05). Of these, three patients had sputum positive pulmonary tuberculosis and one each had sputum negative pulmonary tuberculosis and tubercular meningitis. All patients were treated with standard anti-tubercular therapy; four patients improved whereas one died due to complications of disease. Systemic CS therapy causes a significant increase in incidence of tuberculosis.
    The Journal of the Association of Physicians of India 10/2000; 48(9):881-4.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To study the efficacy of isoniazid prophylaxis (INHP) in patients with systemic lupus erythematosus (SLE) receiving long term glucocorticosteroid treatment. Treatment with INHP (5 mg/kg/day, max 300 mg/day) together with pyridoxine 10 mg/day for one year was started in all patients with SLE seen between January 1994 and December 1999 and followed up thereafter. Clinical examination and chest radiography were carried out in all patients before the start of INHP treatment. A liver profile was obtained only if liver toxicity was suspected owing to nausea, loss of appetite, and icterus. Only the data of those patients who completed the INHP treatment or who were withdrawn owing to toxicity have been analysed. This was compared with the results of an earlier study of the incidence of tuberculosis (TB) in patients with SLE not receiving INHP. Ninety seven patients were included, of whom 95 completed one year's treatment with INHP. Treatment was discontinued in two owing to toxicity: hepatitis in one and peripheral neuropathy in one, at eight and 10 months, respectively. One patient developed TB within one month of starting INHP. Seventy patients were followed up further for at least one year (mean 26.4 months, range 12-60 months) after completion of the INHP treatment. During this period one patient developed TB after one month. No deaths due to TB or hepatitis occurred. In comparison with earlier series the incidence of TB decreased from 11% to 2%, a reduction of 82%. The cost of treatment for each case of TB prevented in the first year was 5800 rupees. INHP is safe and effective in SLE.
    Annals of the Rheumatic Diseases 04/2002; 61(3):251-3. DOI:10.1136/ard.61.3.251 · 10.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To determine the risk factors associated with and to describe the clinical course of tuberculosis (TB) in patients with systemic lupus erythematosus (SLE). Clinical features of patients with TB during the 1-year period prior to the diagnosis of TB were compared with controls. Of the 526 SLE patients, 57 (11%) had TB. Extra-pulmonary or miliary TB occurred in 67%. Patients with TB were more likely to have organic brain syndrome, vasculitis, and nephritis: and they were also more likely to have received intravenous 'pulse' methylprednisolone or high cumulative dose of prednisolone. The cumulative dose of prednisolone and presence of nephritis were independent risk factors for the development of TB using multivariate regression analysis. There is a high prevalence of TB, especially extra-pulmonary diseases, among SLE patients in Hong Kong. High cumulative dose of corticosteroid and lupus nephritis are important risk factors for the development of TB.
    Scandinavian Journal of Rheumatology 02/2002; 31(5):296-300. DOI:10.1080/030097402760375205 · 2.53 Impact Factor